Timothy Eisen
University of Cambridge · 109 works · 4,280 citations · h-index 27
Top works
- Common 5p15.33 and 6p21.33 variants influence lung cancer risk
- A Genome-wide Association Study of Lung Cancer Identifies a Region of Chromosome 5p15 Associated with Risk for Adenocarcinoma
- A Genome-wide Association Study of Lung Cancer Identifies a Region of Chromosome 5p15 Associated with Risk for Adenocarcinoma
- Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer
- Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer
- Deciphering the Impact of Common Genetic Variation on Lung Cancer Risk: A Genome-Wide Association Study
- Familial Aggregation of Common Sequence Variants on 15q24-25.1 in Lung Cancer
- Phase III randomised comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC)
- Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC).
- Experience with sorafenib and adverse event management
- Inherited Variation at Chromosome 12p13.33, Including RAD52 , Influences the Risk of Squamous Cell Lung Carcinoma
- Chromosome 15q25 (CHRNA3-CHRNA5) Variation Impacts Indirectly on Lung Cancer Risk
- Pleiotropic Associations of Risk Variants Identified for Other Cancers With Lung Cancer Risk: The PAGE and TRICL Consortia
- Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma
- Variation in TP63 is Associated with Lung Adenocarcinoma in the UK Population
- Common Variation at 1q24.1 (ALDH9A1) Is a Potential Risk Factor for Renal Cancer
- Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials
- Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients
- Identification of lung cancer histology-specific variants applying Bayesian framework variant prioritization approaches within the TRICL and ILCCO consortia
- Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma